Vantive, a major US-based medtech firm, has announced plans to build a new factory in Ħal Far focused on developing products for renal patients.

Announcing the €150 million investment today, Senior Director Brian Tabone said the factory is expected to start operating in 2029 and employ around 250 people by the time it is fully operational.

The new factory will be built on a 16,000 sqm site. Works are set to begin later in 2026, with construction completed in 2027 and the factory expected to be fully operational by 2029.

The Maltese Government has hailed this investment as one of the largest ever foreign direct investments in Maltese history.

Prime Minister Robert Abela described Vantive’s investment in Malta as a historic moment which will “create 250 new, high-quality careers, many of which will be in the science and technology sectors.”

Vantive used to form part of Baxter, which has long had a presence in Malta, but launched as a standalone company in 2025 following its acquisition by funds managed by Carlyle, one of the world’s largest private equity firms.

It focuses on therapies for chronic kidney disease and acute kidney injury.

Department of Information / Clifton Fenech